Smac modulates chemosensitivity in head and neck cancer cells through the mitochondrial apoptotic pathway
Quanhong Sun1, Xingnan Zheng, Lin Zhang
1University of Pittsburgh Cancer Institute, Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA.
Purpose:
Overexpression of inhibitors of apoptosis proteins (IAP) contributes to therapeutic resistance. Second mitochondria-derived activator of caspase (Smac) promotes caspase activation by binding to IAPs upon release from the mitochondria. IAP antagonists, also called SMAC mimetics, are promising anticancer agents modeled after this mechanism. We investigated the role and mechanisms of Smac- and Smac mimetic-mediated chemosensitization in head and neck squamous cell carcinoma (HNSCC) cells.
Experimental Design:
The effects of SMAC knockdown, SMAC overexpression, and a small molecule Smac mimetic on the chemosensitivities of HNSCC cells were determined. The mechanisms of Smac- and Smac mimetic-mediated chemosensitization were investigated by analyzing growth suppression, the mitochondrial apoptotic pathway, caspase activation, and IAP proteins. The therapeutic responses of HNSCC cells with different levels of Smac were compared in xenograft models.
Results:
We found that Smac mediates apoptosis induced by several classes of therapeutic agents through the mitochondrial pathway. SMAC knockdown led to impaired caspase activation, mitochondrial membrane depolarization, and release of cytochrome c. A small molecule Smac mimetic, at nanomolar concentrations, significantly sensitized HNSCC cells to gemcitabine-induced apoptosis and restored gemcitabine sensitivity in SMAC knockdown cells, through caspase activation, X-linked IAP dissociation, and mitochondria-associated events, but not the TNF-α pathway. Furthermore, Smac levels modulated the therapeutic response of HNSCC cells to gemcitabine in xenograft models.
Conclusions:
Our results establish a critical role of Smac in mediating therapeutic responses of HNSCC cells and provide a strong rationale for combining Smac mimetics with other anticancer agents to treat HNSCC.
Insights
Second mitochondria-derived activator of caspase (Smac) plays a key role in head and neck cancer therapy. Smac mimetics enhance chemotherapy effectiveness by promoting apoptosis and overcoming resistance.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Inhibitors of apoptosis proteins (IAP) overexpression drives therapeutic resistance in cancers.
- Second mitochondria-derived activator of caspase (Smac) antagonizes IAPs, promoting apoptosis.
- Smac mimetics are a novel class of anticancer agents targeting IAPs.
Purpose of the Study:
- To investigate the role of Smac in mediating chemosensitization in head and neck squamous cell carcinoma (HNSCC).
- To elucidate the mechanisms underlying Smac and Smac mimetic-induced chemosensitization.
- To evaluate the therapeutic potential of Smac mimetics in HNSCC models.
Main Methods:
- Assessed effects of SMAC knockdown, overexpression, and a small molecule Smac mimetic on HNSCC chemosensitivity.
- Analyzed growth suppression, mitochondrial apoptotic pathway activation, caspase activation, and IAP protein levels.
- Compared therapeutic responses in HNSCC xenograft models with varying Smac levels.
Main Results:
- Smac mediates apoptosis induced by various therapeutic agents via the mitochondrial pathway.
- SMAC knockdown impaired caspase activation and cytochrome c release.
- Smac mimetic sensitized HNSCC cells to gemcitabine, restoring sensitivity in SMAC knockdown cells.
- Smac levels influenced HNSCC response to gemcitabine in vivo.
Conclusions:
- Smac critically mediates therapeutic responses in HNSCC cells.
- Combining Smac mimetics with chemotherapy presents a strong therapeutic strategy for HNSCC.
Related Concept Videos
The Intrinsic Apoptotic Pathway
Apoptosis
The Extrinsic Apoptotic Pathway
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...


